» Articles » PMID: 19158483

Molecular Phenotyping of Human Ovarian Cancer Stem Cells Unravels the Mechanisms for Repair and Chemoresistance

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2009 Jan 23
PMID 19158483
Citations 268
Authors
Affiliations
Soon will be listed here.
Abstract

A major burden in the treatment of ovarian cancer is the high percentage of recurrence and chemoresistance. Cancer stem cells (CSCs) provide a reservoir of cells that can self-renew, can maintain the tumor by generating differentiated cells [non-stem cells (non-CSCs)] which make up the bulk of the tumor and may be the primary source of recurrence. We describe the characterization of human ovarian cancer stem cells (OCSCs). These cells have a distinctive genetic profile that confers them with the capacity to recapitulate the original tumor, proliferate with chemotherapy, and promote recurrence. CSC identified in EOC cells isolated form ascites and solid tumors are characterized by: CD44+, MyD88+, constitutive NFkappaB activity and cytokine and chemokine production, high capacity for repair, chemoresistance to conventional chemotherapies, resistance to TNFalpha-mediated apoptosis, capacity to form spheroids in suspension, and the ability to recapitulate in vivo the original tumor. Chemotherapy eliminates the bulk of the tumor but it leaves a core of cancer cells with high capacity for repair and renewal. The molecular properties identified in these cells may explain some of the unique characteristics of CSCs that control self-renewal and drive metastasis. The identification and cloning of human OCSCs can aid in the development of better therapeutic approaches for ovarian cancer patients.

Citing Articles

Targeting HSP90 in Gynecologic Cancer: Molecular Mechanisms and Therapeutic Approaches.

Min L, Li X, Liang L, Ruan Z, Yu S Cell Biochem Biophys. 2024; 83(1):177-192.

PMID: 39249180 DOI: 10.1007/s12013-024-01502-7.


Adipose microenvironment promotes hypersialylation of ovarian cancer cells.

Fox A, Leonard G, Adzibolosu N, Wong T, Tedja R, Sharma S Front Oncol. 2024; 14:1432333.

PMID: 39104719 PMC: 11299042. DOI: 10.3389/fonc.2024.1432333.


STAU1-mediated CNBP mRNA degradation by LINC00665 alters stem cell characteristics in ovarian cancer.

Liu X, Chen Y, Li Y, Bai J, Zeng Z, Wang M Biol Direct. 2024; 19(1):59.

PMID: 39080743 PMC: 11288052. DOI: 10.1186/s13062-024-00506-w.


Plasticity and resistance of cancer stem cells as a challenge for innovative anticancer therapies - do we know enough to overcome this?.

Knopik-Skrocka A, Sempowicz A, Piwocka O EXCLI J. 2024; 23:335-355.

PMID: 38655094 PMC: 11036066. DOI: 10.17179/excli2024-6972.


Informed by Cancer Stem Cells of Solid Tumors: Advances in Treatments Targeting Tumor-Promoting Factors and Pathways.

MacLean M, Walker O, Arun R, Fernando W, Marcato P Int J Mol Sci. 2024; 25(7).

PMID: 38612911 PMC: 11012648. DOI: 10.3390/ijms25074102.


References
1.
Hambardzumyan D, Becher O, Holland E . Cancer stem cells and survival pathways. Cell Cycle. 2008; 7(10):1371-8. DOI: 10.4161/cc.7.10.5954. View

2.
Dean M, Fojo T, Bates S . Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-84. DOI: 10.1038/nrc1590. View

3.
Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

4.
Dingli D, Traulsen A, Pacheco J . Stochastic dynamics of hematopoietic tumor stem cells. Cell Cycle. 2007; 6(4):461-6. DOI: 10.4161/cc.6.4.3853. View

5.
Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T . Identification of human brain tumour initiating cells. Nature. 2004; 432(7015):396-401. DOI: 10.1038/nature03128. View